New biotech business model will 'address pharma's research outsourcing trend'
This article was originally published in Scrip
The German biotech company 4SC has decided to transfer most of its early-stage research activities to a 100%-owned subsidiary. "We are convinced this new business model addresses the current trends in the pharma industry to collaborate more in early stage R&D," Dr Ulrich Dauer, CEO of 4SC, told Scrip.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.